Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers.


Journal

Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526

Informations de publication

Date de publication:
2021
Historique:
entrez: 1 11 2021
pubmed: 2 11 2021
medline: 4 1 2022
Statut: epublish

Résumé

γδ T lymphocytes diverge from conventional T CD8 lymphocytes for ontogeny, homing, and antigen specificity, but whether their differentiation in tumors also deviates was unknown. Using innovative analyses of our original and ~150 published single-cell RNA sequencing datasets validated by phenotyping of human tumors and murine models, here we present the first high-resolution view of human γδ T cell differentiation in cancer. While γδ T lymphocytes prominently encompass TCRVγ9 cells more differentiated than T CD8 in healthy donor's blood, a different scenario is unveiled in tumors. Solid tumors and lymphomas are infiltrated by a majority of TCRVγnon9 γδ T cells which are quantitatively correlated and remarkably aligned with T CD8 for differentiation, exhaustion, gene expression profile, and response to immune checkpoint therapy. This cancer-wide association is critical for developing cancer immunotherapies.

Identifiants

pubmed: 34721945
doi: 10.1080/2162402X.2021.1939518
pii: 1939518
pmc: PMC8555559
doi:

Substances chimiques

Receptors, Antigen, T-Cell, gamma-delta 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1939518

Informations de copyright

© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

Références

Nature. 2018 May;557(7706):575-579
pubmed: 29769722
Cell. 2017 Nov 2;171(4):934-949.e16
pubmed: 29033130
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Cancer Immunol Res. 2020 Jul;8(7):869-882
pubmed: 32295784
J Exp Med. 2003 Aug 4;198(3):391-7
pubmed: 12900516
Nat Biotechnol. 2014 Apr;32(4):381-386
pubmed: 24658644
Annu Rev Immunol. 2004;22:745-63
pubmed: 15032595
Nat Rev Immunol. 2012 Nov;12(11):762-73
pubmed: 23018291
Nat Methods. 2018 Apr;15(4):267-270
pubmed: 29529018
Nature. 2018 Jun;558(7710):454-459
pubmed: 29899446
Cell Rep. 2017 Sep 19;20(12):2921-2934
pubmed: 28930685
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
Cancer Discov. 2020 Mar;10(3):406-421
pubmed: 31857391
Nat Med. 2018 Jul;24(7):986-993
pubmed: 29942092
Br J Haematol. 2021 Feb;192(3):415
pubmed: 33386647
Nucleic Acids Res. 2019 Dec 2;47(21):e133
pubmed: 31294801
Oncoimmunology. 2016 May 19;5(7):e1188246
pubmed: 27622044
Immunity. 2010 Aug 27;33(2):229-40
pubmed: 20727791
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31689241
Clin Cancer Res. 2019 Jul 15;25(14):4443-4454
pubmed: 31010835
Nat Methods. 2017 Sep;14(9):865-868
pubmed: 28759029
Cell. 2018 Aug 23;174(5):1293-1308.e36
pubmed: 29961579
J Clin Invest. 1999 May 15;103(10):1437-49
pubmed: 10330426
Nature. 2019 Jul;571(7764):265-269
pubmed: 31207605
Nat Commun. 2018 Jan 2;9(1):32
pubmed: 29296022
Immunol Rev. 2020 Nov;298(1):47-60
pubmed: 33191519
Nat Biotechnol. 2019 May;37(5):547-554
pubmed: 30936559
Science. 2020 Aug 21;369(6506):942-949
pubmed: 32820120
Nat Med. 2017 Jan 6;23(1):18-27
pubmed: 28060797
Curr Opin Immunol. 2013 Oct;25(5):556-63
pubmed: 24148236
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Nature. 2017 Aug 31;548(7669):537-542
pubmed: 28783722
Sci Transl Med. 2021 Jan 20;13(577):
pubmed: 33472952
Oncoimmunology. 2017 Jul 13;6(10):e1347742
pubmed: 29123962
Nat Commun. 2020 May 8;11(1):2285
pubmed: 32385277
Nat Immunol. 2020 Dec;21(12):1552-1562
pubmed: 33046887
Cell. 2016 Sep 22;167(1):203-218.e17
pubmed: 27641500
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):3163-3168
pubmed: 28270598
Eur J Immunol. 2005 Jun;35(6):1764-72
pubmed: 15915537
Annu Rev Immunol. 2020 Apr 26;38:487-510
pubmed: 32017636
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
NAR Genom Bioinform. 2020 Apr 20;2(2):lqaa025
pubmed: 33575582
Res Immunol. 1996 Jun;147(5):338-47
pubmed: 8876063
Nat Rev Drug Discov. 2020 Mar;19(3):169-184
pubmed: 31492944
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11906-11915
pubmed: 31118283
Sci Transl Med. 2019 Oct 9;11(513):
pubmed: 31597756
Oncoimmunology. 2017 Feb 6;6(3):e1284723
pubmed: 28405516
Immunity. 2020 Jan 14;52(1):183-199.e9
pubmed: 31924475
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Nat Commun. 2020 Mar 5;11(1):1201
pubmed: 32139671
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Blood. 2004 Sep 15;104(6):1801-7
pubmed: 15178578
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Nat Med. 2018 Aug;24(8):1277-1289
pubmed: 29988129
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32527931
Nature. 2020 Mar;579(7798):274-278
pubmed: 32103181
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
J Am Soc Nephrol. 2010 Jan;21(1):181-8
pubmed: 19713314
J Clin Invest. 2016 Sep 1;126(9):3447-52
pubmed: 27525433
Cancer Res. 2017 Jul 1;77(13):3540-3550
pubmed: 28487385
Nat Med. 2020 Feb;26(2):193-199
pubmed: 32042196

Auteurs

Juan-Pablo Cerapio (JP)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.

Marion Perrier (M)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.

Camille-Charlotte Balança (CC)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.

Pauline Gravelle (P)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.
Institut Carnot Lymphome CALYM, France.
Centre Hospitalier Universitaire, Toulouse, France.

Fréderic Pont (F)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.

Christel Devaud (C)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.

Don-Marc Franchini (DM)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.
Institut Carnot Lymphome CALYM, France.
Institut Claudius Regaud, Toulouse, France.

Virginie Féliu (V)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.

Marie Tosolini (M)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.

Carine Valle (C)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.

Fréderic Lopez (F)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.

Anne Quillet-Mary (A)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.
Institut Carnot Lymphome CALYM, France.

Loic Ysebaert (L)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.
Institut Carnot Lymphome CALYM, France.
Centre Hospitalier Universitaire, Toulouse, France.

Alejandra Martinez (A)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.

Jean Pierre Delord (JP)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Institut Claudius Regaud, Toulouse, France.

Maha Ayyoub (M)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.

Camille Laurent (C)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.
Institut Carnot Lymphome CALYM, France.
Centre Hospitalier Universitaire, Toulouse, France.

Jean-Jacques Fournie (JJ)

Centre de Recherches en Cancérologie de Toulouse, INSERM UMR1037, Toulouse, France.
Toulouse University, Toulouse, France.
CNRS UMR 5071, Toulouse, France.
Institut Universitaire du Cancer-Oncopole de Toulouse, Toulouse, France.
Laboratoire d'Excellence 'TOUCAN-2', Toulouse, France.
Institut Carnot Lymphome CALYM, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH